President Donald Trump unveiled a two-pronged plan to improve affordability and accessibility of in vitro fertilization (IVF) treatments. Speaking from the Oval Office, he emphasized the initiative’s potential to reduce IVF costs substantially and support American families.
Encouraging Employers to Offer Fertility Benefits
The administration will promote fertility benefits as supplemental insurance options for employees, akin to vision and dental coverage. New Labor Department guidance aims to simplify the process for employers, including small businesses, to offer fertility insurance without the need to change existing primary health plans. Participation, however, remains voluntary and without government subsidies.
Significant Drug Discounts via Government Partnership
Trump announced an agreement with EMD Serono, manufacturer of the widely used fertility drug Gonal-F, to provide steep discounts on fertility medications. These drugs will be available at prices reduced by up to 73% through a government platform, TrumpRx.gov, starting next year. EMD Serono stated eligible patients could purchase drugs at an 84% discount off list prices.
Potential Impact on IVF Costs and Family Health
While fertility medications represent only part of IVF costs—which can exceed $20,000 per cycle—including procedures like ultrasounds and embryo storage, the announced drug discounts could alleviate a significant financial burden for many couples. Trump highlighted that easier access to fertility insurance might enable earlier detection and treatment of reproductive issues, leading to healthier pregnancies and children.
Current Coverage Gaps and Policy Context
Data from the Kaiser Family Foundation shows only about 25% of large employers currently offer IVF coverage, and few states mandate fertility treatment insurance. Despite some existing benefits in insurance plans, most patients face substantial out-of-pocket expenses. Trump’s plan reflects a partial fulfillment of his 2024 campaign pledge to make fertility treatments universally accessible and insured, reinforcing infertility as a key family issue.
Reactions and Limitations of the Plan
While praised by certain fertility advocacy groups for expanding access, critics caution that reliance on voluntary employer participation limits the program’s reach. Concerns also remain about how much these drug discounts will reduce total IVF expenses for middle-income families, who still must cover other costs. The administration’s measures stop short of mandating insurance coverage or directly subsidizing patients.
Infertility affects approximately one in six women of reproductive age globally, with IVF accounting for about 2% of births in the U.S. This policy shift marks the Trump administration’s most significant action on fertility care to date, attempting to balance political and health considerations amid ongoing debates about embryo rights and reproductive access.
Related topics
